With active pharmaceutical ingredient sales of $1,460m (€960.8m) in
2007 and a portfolio of more than 250 compounds, Teva
Pharmaceutical Industries is by a long stretch the dominant
supplier in the global API market.
Generics giant Teva has announced results for the second quarter of
the financial year showing record-breaking sales, thanks to an
impressive performance from MS drug Copaxone (glatiramer acetate)
and the early launch of generic Lotrel...
Teva Pharmaceutical Industries' active pharmaceutical ingredients
(API) business is on track to become a $1 billion enterprise this
year, although growth in the first quarter of this year was almost
entirely from in-house sales,...
Teva Hungary, a subsidiary of number two generic company Teva
Pharmaceuticals, is to build a $100 million (€75m) factory for the
production of active pharmaceutical ingredients (APIs) in